Home/Services/Licensing
Services

Licensing

We in-license and out-license assets from the clinical stage through to late commercial stage, with a clear focus on the MENA region.

Four ways to work with us

Clinical assets

We license clinical assets that already show proof of concept (beyond Phase 1), with options for joint development to take the asset forward in the region.

Recently approved products

Drugs approved by the USFDA or EMA, including small molecules, biologics and gene-editing therapies, with continued post-marketing clinical development where needed.

Commercial assets

Branded generics, generics, biosimilars, biobetters and any asset that can improve access to therapy for patients in the region.

In-licensing & out-licensing

Out-licensing connects you with partners in MENA through our network of pharma companies, medtech start-ups and research institutions. In-licensing helps you find the right regional partner, with deal structures customized to your needs.

Why license through AcedrA?

  • A pipeline-tracking practice covering more than 1,000 biotech and medical companies
  • Regulatory, medical and distribution capabilities under one roof
  • Local presence in Saudi Arabia, the UAE and Tunisia
  • A hybrid model: we can both develop and commercialize

Start a licensing conversation

Tell us about your asset or what you are looking for.

Start now